2007
DOI: 10.1136/aim.25.4.200
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Juvenile Stroke Using Yamamoto New Scalp Acupuncture (Ynsa) – a Case Report

Abstract: In Germany, stroke affects approximately 300 children each year. Treatment options for stroke patients, particularly for children, are limited. A case is described of an 18 month old girl with hemiparesis, who showed a considerable degree of recovery over the course of 21 months while receiving Yamamoto New Scalp Acupuncture using soft laser. This may represent a new option for the therapy of such patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0
2

Year Published

2009
2009
2019
2019

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 18 publications
(8 citation statements)
references
References 2 publications
0
6
0
2
Order By: Relevance
“…Earlier studies have reported the clinical utility of YNSA in patients with cerebrovascular disorders, particularly those with stroke. 12,13 The findings of this study may extend the clinical application of YNSA to patients with migraine.…”
Section: Discussionmentioning
confidence: 87%
“…Earlier studies have reported the clinical utility of YNSA in patients with cerebrovascular disorders, particularly those with stroke. 12,13 The findings of this study may extend the clinical application of YNSA to patients with migraine.…”
Section: Discussionmentioning
confidence: 87%
“…Yamamoto Schockert e Boroojerdi 24 relataram que a craniopuntura é uma técnica utilizada também para o alívio da dor, que não apresenta efeitos colaterais e pode reduzir drasticamente o consumo de medicamentos. Fato comprovado no presente estudo, onde a paciente não precisou fazer uso de medicamento para analgesia durante a intervenção e não apresentou efeitos colaterais com a aplicação da técnica.…”
Section: Discussionunclassified
“…Yamamoto und andere Autoren veröffentlichten Case-Reports über YNSA bei neurologischen Erkrankungen [3,10].…”
Section: Wissenschaftliche Datenlageunclassified